# Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/atopic-dermatitis-timing-of-pediatric-studies-during-development-of-systemic-drugs/287c413c-cc5e-49ee-af83-9d7183bc4f4d

> FDA guidance document: Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs. Issue date: October 03, 2018. Get complete insights and analysis.

---

## Details

- Title: Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2018-10-03
- Last Changed: 2024-04-11
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-1175">FDA-2018-D-1175</a>

## Related Documents

- [Pediatric HIV Infection: Drug Development for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-hiv-infection-drug-development-for-treatment/2fd110e1-e45d-44ba-8efb-87a9ba7b8d23)
- [Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-for-treatment-guidance-for-industry/a2b09b4f-527f-406f-a71d-c6e62d4737ad)
- [Clinical Trial Imaging Endpoint Process Standards Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-imaging-endpoint-process-standards-guidance-for-industry/910804b6-9e1d-47f8-8105-89b586c9622b)